- Home
- GF vs CLYM Comparison
GF vs CLYM Comparison
Compare GF & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GF
- CLYM
- Stock Information
- Founded
- GF 1990
- CLYM 2018
- Country
- GF Germany
- CLYM United States
- Employees
- GF N/A
- CLYM N/A
- Industry
- GF Investment Managers
- CLYM
- Sector
- GF Finance
- CLYM
- Exchange
- GF Nasdaq
- CLYM NYSE
- Market Cap
- GF 126.8M
- CLYM 101.6M
- IPO Year
- GF N/A
- CLYM 2021
- Fundamental
- Price
- GF $8.82
- CLYM $1.47
- Analyst Decision
- GF
- CLYM
- Analyst Count
- GF 0
- CLYM 0
- Target Price
- GF N/A
- CLYM N/A
- AVG Volume (30 Days)
- GF 28.1K
- CLYM 315.3K
- Earning Date
- GF 01-01-0001
- CLYM 03-27-2025
- Dividend Yield
- GF 0.82%
- CLYM N/A
- EPS Growth
- GF N/A
- CLYM N/A
- EPS
- GF N/A
- CLYM N/A
- Revenue
- GF N/A
- CLYM N/A
- Revenue This Year
- GF N/A
- CLYM N/A
- Revenue Next Year
- GF N/A
- CLYM N/A
- P/E Ratio
- GF N/A
- CLYM N/A
- Revenue Growth
- GF N/A
- CLYM N/A
- 52 Week Low
- GF $7.38
- CLYM $1.41
- 52 Week High
- GF $9.41
- CLYM $11.55
- Technical
- Relative Strength Index (RSI)
- GF 67.31
- CLYM N/A
- Support Level
- GF $8.81
- CLYM N/A
- Resistance Level
- GF $8.99
- CLYM N/A
- Average True Range (ATR)
- GF 0.10
- CLYM 0.00
- MACD
- GF 0.03
- CLYM 0.00
- Stochastic Oscillator
- GF 77.33
- CLYM 0.00
About GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a United States-based non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.